Condition: Treatment Resistant Depression · Chronic Pain · Sponsor: Centre for Addiction and Mental Health
Psilocybin, the chemical component of "magic mushrooms", has been administered with psychotherapy in several randomized clinical trials (RCTs) showing large and sustained antidepressant effects. The purpose of this study is to assess the feasibility, tolerability, and preliminary efficacy of psilocybin therapy for adults with chronic neuropathic pain and co-morbid treatment resistant depression.
This description comes directly from the study's public registry record.
Muhammad Ishrat Husain, MBBS, MD · 4165358501 · ishrat.husain@camh.ca
Alexandria Coles, MSc. · 4165358501 · alexandria.coles@camh.ca
Always discuss trial participation with your own doctor first.
| Centre for Addiction and Mental Health | Toronto, Ontario, Canada | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06518720